Biocon completes acquisition of balance stake in Biocon Biologics from Mylan

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹365.00

prior close

₹365.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.2%+0.8% vs market

Pharmaceuticals peers, median of 156sector+1.2%+0.9% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Midcap 150 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.5

15m

+2.1

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.1+1.2+0.8+1.2+0.9

Next day

+0.6-0.5+1.1+0.0+0.6

-0.5+0.0-0.5-0.7+0.2

+1.4+1.6-0.3+0.2+1.2

-0.1+1.7-1.8-0.3+0.2

+0.6+1.8-1.2+0.1+0.5

+1.9+3.6-1.6+2.4-0.5

15d

+3.6+3.6-0.0+2.7+0.9

+6.2+3.6+2.6+1.2+5.0

+0.5-7.9+8.5-8.5+9.1

-1.9+5.1-7.0+3.5-5.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon has completed acquiring the remaining 7,18,34,691 equity shares of its unlisted material subsidiary Biocon Biologics Limited (BBL) from Mylan Inc. for USD 200 million in cash. This is the second tranche, following an equal-sized purchase completed on January 5, 2026. In total, Biocon acquired 14,36,69,382 BBL shares from Mylan for USD 400 million. Post this, Biocon holds about 98% of BBL on a fully diluted basis.

Likely market impact

Raises Biocon's stake in BBL to about 98%, simplifying the subsidiary structure. Cash outflow of USD 200 million for the second tranche.